LeukoScan

RSS
Withdrawn

This medicine's authorisation has been withdrawn

sulesomab
Medicine Human Withdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 30 January 2018, the European Commission withdrew the marketing authorisation for LeukoScan (sulesomab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Immunomedics GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

LeukoScan was granted marketing authorisation in the EU on 14 February 1997 for diagnostic imaging in suspected osteomyelitis. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in year 2002. It was then granted unlimited validity in 2007. 

The European Public Assessment Report (EPAR) for LeukoScan is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

LeukoScan : EPAR - Summary for the public

English (EN) (516.27 KB - PDF)

First published: Last updated:
View

български (BG) (716 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

español (ES) (517.76 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

čeština (CS) (685.63 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

dansk (DA) (517.71 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Deutsch (DE) (519.14 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

eesti keel (ET) (516.76 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

ελληνικά (EL) (711.69 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

français (FR) (516.17 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

italiano (IT) (519.32 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

latviešu valoda (LV) (690.36 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

lietuvių kalba (LT) (656.6 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

magyar (HU) (676.17 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Malti (MT) (688.96 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Nederlands (NL) (518.44 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

polski (PL) (691.01 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

português (PT) (520.24 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

română (RO) (650.61 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

slovenčina (SK) (680.33 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

slovenščina (SL) (673.42 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Suomi (FI) (516.88 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

svenska (SV) (517.53 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Product information

LeukoScan : EPAR - Product Information

English (EN) (611.18 KB - PDF)

First published: Last updated:
View

български (BG) (1.27 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

español (ES) (624.63 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

čeština (CS) (1.06 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

dansk (DA) (670.18 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Deutsch (DE) (623.7 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

eesti keel (ET) (616.86 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

ελληνικά (EL) (1.25 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

français (FR) (684.89 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

hrvatski (HR) (752.92 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

íslenska (IS) (612.91 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

italiano (IT) (613.84 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

latviešu valoda (LV) (1.15 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

lietuvių kalba (LT) (786.25 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

magyar (HU) (1.03 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Malti (MT) (975.04 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Nederlands (NL) (622.94 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

norsk (NO) (606.27 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

polski (PL) (1.08 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

português (PT) (679.29 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

română (RO) (733.17 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

slovenčina (SK) (1.04 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

slovenščina (SL) (1.03 MB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

Suomi (FI) (610.22 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View

svenska (SV) (667.87 KB - PDF)

First published: 13/08/2007 Last updated: 09/02/2018
View
Latest procedure affecting product information:IAIN/0024/G
18/01/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

LeukoScan : EPAR - All Authorised presentations

English (EN) (466.59 KB - PDF)

First published: Last updated:
View

Product details

Name of medicine
LeukoScan
Active substance
sulesomab
International non-proprietary name (INN) or common name
sulesomab
Therapeutic area (MeSH)
  • Osteomyelitis
  • Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
VO4D

Pharmacotherapeutic group

Diagnostic agents

Therapeutic indication

This medicinal product is for diagnostic use only.

LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.

LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.

Authorisation details

EMA product number
EMEA/H/C/000111
Marketing authorisation holder
Immunomedics GmbH

Otto-Röhm-Straße 69
D-64293 Darmstadt
Germany

Marketing authorisation issued
14/02/1997
Withdrawal of marketing authorisation
30/01/2018
Revision
7

Assessment history

LeukoScan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (566.84 KB - PDF)

First published: Last updated:
View

LeukoScan : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (571.74 KB - PDF)

First published: Last updated:
View

LeukoScan : EPAR - Scientific Discussion

English (EN) (692.83 KB - PDF)

First published: Last updated:
View

LeukoScan : EPAR - Procedural steps taken before authorisation

English (EN) (548.33 KB - PDF)

First published: Last updated:
View
This page was last updated on

Share this page

Back to top